Viromed Medical AG (Q11) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Viromed Medical AG (Q11) has a cash flow conversion efficiency ratio of -0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.12 Million ≈ $-11.83 Million USD) by net assets (€269.20 Million ≈ $314.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Viromed Medical AG market cap and net worth for the company's overall valuation and market capitalisation.
Viromed Medical AG - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Viromed Medical AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Viromed Medical AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viromed Medical AG ranked by their cash flow conversion efficiency. See Viromed Medical AG debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dnake Xiamen Intelligent Technology
SHE:300884
|
0.634x |
|
Cimentas Izmir Cimento Fabrikasi TAS
IS:CMENT
|
0.007x |
|
Shenmao Technology Inc
TW:3305
|
-0.033x |
|
EUROKAI GmbH & Co. KGaA
F:EUK3
|
0.017x |
|
Bannari Amman Sugars Limited
NSE:BANARISUG
|
0.130x |
|
Yuancheng Cable Co Ltd
SHE:002692
|
0.150x |
|
DHG Pharmaceutical JSC
VN:DHG
|
0.063x |
|
Jay Mart Public Company Limited
BK:JMART
|
0.025x |
Annual Cash Flow Conversion Efficiency for Viromed Medical AG (2021–2024)
The table below shows the annual cash flow conversion efficiency of Viromed Medical AG from 2021 to 2024. View Viromed Medical AG share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €201.16 Million ≈ $235.17 Million |
€-6.03 Million ≈ $-7.04 Million |
-0.030x | +94.36% |
| 2023-12-31 | €64.28 Million ≈ $75.15 Million |
€-34.16 Million ≈ $-39.93 Million |
-0.531x | -60.96% |
| 2022-12-31 | €63.23 Million ≈ $73.92 Million |
€-20.87 Million ≈ $-24.40 Million |
-0.330x | +40.80% |
| 2021-12-31 | €39.97 Million ≈ $46.73 Million |
€-22.29 Million ≈ $-26.06 Million |
-0.558x | -- |
About Viromed Medical AG
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.